{"id":85101,"date":"2026-06-16T07:35:00","date_gmt":"2026-06-16T07:35:00","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/85101\/"},"modified":"2026-06-16T07:35:00","modified_gmt":"2026-06-16T07:35:00","slug":"novartis-launches-prostate-cancer-drug","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/85101\/","title":{"rendered":"Novartis launches prostate cancer drug"},"content":{"rendered":"<p>New Delhi: Novartis India on Monday announced the launch of Pluvicto, a precision radiotherapy for prostate cancer. Pluvicto is the country&#8217;s first regulatory authority-approved radioligand therapy for eligible patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer, Novartis India said in a statement. Designed to precisely target prostate cancer cells while minimising exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India, it added.   <\/p>\n","protected":false},"excerpt":{"rendered":"New Delhi: Novartis India on Monday announced the launch of Pluvicto, a precision radiotherapy for prostate cancer. Pluvicto&hellip;\n","protected":false},"author":2,"featured_media":85102,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,9922,31818,4117,9389,8514],"class_list":["post-85101","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-novartis-india","tag-pluvicto","tag-prostate-cancer","tag-psma","tag-radioligand-therapy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116758638087301939","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/85101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=85101"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/85101\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/85102"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=85101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=85101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=85101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}